| Autor: |
Nusrat Bholah, D Allen, Leanne Jo Holmes, Robert Niven, L Elsey, G Tavernier |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Airway pharmacology and treatment. |
| DOI: |
10.1183/13993003.congress-2019.pa2512 |
| Popis: |
Background: Manchester severe asthma team have treated 243 patients to date with Mepolizumab since it became available in the UK for the treatment of severe eosinophilic asthma in April 2017. Patients are weaned off their maintenance steroids following a standard protocol and offered a synacthen test when their prednisolone (Pred) reaches 7.5mg daily and their morning cortisol levels are below 100nmol/l to determine if they are adrenally suppressed (AS) or competent (AC). Our assay is unaffected by Pred dose. Aim: To determine the incidence of AS patients on Mepolizumab. Methods: We retrospectively collected data for the patients that had undergone a synacthen test. AS was confirmed if 60 min post-stimulation cortisol levels Results: Data on 51 patients was available: Mean (SD) or median (range): age 50(14) yrs, BMI 27(20-53) kg/m2, 55% female, FEV1 64(31)% predicted, IgE 110 (10-6800) IU/ml, FeNO 24(0-204) ppb, blood eosinophils 0.14(0.01-1.35)x109/l with no patient on maintenance steroids other than oral Pred. A further 55 patients were awaiting synacthen testing. The data shows that 65% patients had adrenal insufficiency. The Pred dose and the number of exacerbations were significantly reduced post treatment, both (p Conclusions: Two thirds of patients on Mepolizumab are adreno-insufficient. Further understanding will be gained as more of these patients reduce their steroids dose and undergo a synacthen test. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
